There are several examples in this area, such as the structure-based virtual screenings of novel small molecules targeting free fatty acid receptor FFAR4 for colorectal cancer [106], or adhesion receptor ADGRF5 for breast cancer [107,108]; or ligand-based screenings of small molecules targeting oxoeicosanoid receptor OXER1 that signal specifically through Gαi and/or Gβγ for prostate cancer [109]. Here, OXER1 is linked to prostate carcinoma.